56741-95-8 Usage
Description
2-AMINO-5-BROMO-4-HYDROXY-6-PHENYLPYRIMIDINE, also known as Bropirimine, is an immunomodulator with diverse biological activities. It is a toll-like receptor 7 (TLR7) agonist that exhibits various effects on the immune system and has potential applications in the treatment of certain cancers and autoimmune diseases. Bropirimine is characterized by its ability to induce interferon and inhibit RANKL-induced osteoclast differentiation in a concentration-dependent manner.
Uses
Used in Anticancer Applications:
2-AMINO-5-BROMO-4-HYDROXY-6-PHENYLPYRIMIDINE is used as an anticancer agent for its potential role in the treatment of superficial bladder cancer (transitional cell carcinoma). It demonstrates direct antitumor activity and may have a cytokine-mediated effect. Additionally, it has been shown to prevent the development of transitional cell carcinomas in a mouse model of carcinogen-induced bladder carcinoma when administered through diet.
Used in Immunostimulation Research:
2-AMINO-5-BROMO-4-HYDROXY-6-PHENYLPYRIMIDINE is used as an immunostimulating agent and TLR7 agonist in interferon cell signaling research. It is compared with other TLR7 agonists such as imiquimod, R-848, and loxoribine. Bropirimine may be utilized in experimental autoimmune encephalomyelitis (EAE) and bladder cancer research.
Used in Autoimmune Disease Research:
In the field of autoimmune disease research, 2-AMINO-5-BROMO-4-HYDROXY-6-PHENYLPYRIMIDINE is used as a therapeutic agent to reduce pulmonary collagen accumulation and bronchoalveolar lavage fluid (BALF) monocyte and eosinophil infiltration in a hamster model of bleomycin-induced lung fibrosis. It also delays disease onset and progression and increases plasma IFN levels in a mouse model of experimental autoimmune encephalomyelitis (EAE).
Used in Pharmaceutical Industry:
2-AMINO-5-BROMO-4-HYDROXY-6-PHENYLPYRIMIDINE is used as a key compound in the pharmaceutical industry for the development of new drugs targeting cancer and autoimmune diseases, due to its immunostimulatory and anticancer properties.
Biochem/physiol Actions
Bropirimine is an immunostimulating agent. The compound induces production of α and β interferons and enhances NK cell function. Bropirimine has antiproliferative effects in cancer cell lines and tumor growth in in vivo models.
Check Digit Verification of cas no
The CAS Registry Mumber 56741-95-8 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,6,7,4 and 1 respectively; the second part has 2 digits, 9 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 56741-95:
(7*5)+(6*6)+(5*7)+(4*4)+(3*1)+(2*9)+(1*5)=148
148 % 10 = 8
So 56741-95-8 is a valid CAS Registry Number.
InChI:InChI=1/C10H8BrN3O/c11-7-8(6-4-2-1-3-5-6)13-10(12)14-9(7)15/h1-5H,(H3,12,13,14,15)
56741-95-8Relevant articles and documents
Pyrimidin-6-yl Trifluoroborate Salts as Versatile Templates for Heterocycle Synthesis
Cousins, David L.,Fricero, Prisca,Kopf, Kenji P. M.,McColl, Elliot J.,Czechtizky, Werngard,Lim, Yee Hwee,Harrity, Joseph P. A.
supporting information, p. 9412 - 9415 (2021/03/29)
We report a novel and general method to access a highly under-studied privileged scaffold—pyrimidines bearing a trifluoroborate at C4, and highlight the broad utility of these intermediates in a rich array of downstream functionalization reactions. This chemistry is underpinned by the unique features of the trifluoroborate group; its robustness provides an opportunity to carry out chemoselective reactions at other positions on the pyrimidine while providing a pathway for elaboration at the C?B bond when suitably activated.
HTS followed by NMR based counterscreening. Discovery and optimization of pyrimidones as reversible and competitive inhibitors of xanthine oxidase
Even?s, Johan,Edfeldt, Fredrik,Lepist?, Matti,Svitacheva, Naila,Synnergren, Anna,Lundquist, Britta,Gr?nse, Mia,R?nnholm, Anna,Varga, Mikael,Wright, John,Wei, Min,Yue, Sherrie,Wang, Junfeng,Li, Chong,Li, Xuan,Chen, Gang,Liao, Yong,Lv, Gang,Tj?rnebo, Ann,Narjes, Frank
, p. 1315 - 1321 (2014/03/21)
The identification of novel, non-purine based inhibitors of xanthine oxidase is described. After a high-throughput screening campaign, an NMR based counterscreen was used to distinguish actives, which interact with XO in a reversible manner, from assay artefacts. This approach identified pyrimidone 1 as a reversible and competitive inhibitor with good lead-like properties. A hit to lead campaign gave compound 41, a nanomolar inhibitor of hXO with efficacy in the hyperuricemic rat model after oral dosing.
5-Substituted 2-amino-6-phenyl-4(3H)-pyrimidinones. Antiviral- and interferon-inducing agents
Wierenga,Skulnick,Stringfellow,Weed,Renis,Eidson
, p. 237 - 239 (2007/10/02)
-
